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Background. We determined the consistency of positive interferon-gamma (IFN-γ) release assays (IGRAs) to detect latent TB
infection (LTBI) over one-year postpartum in HIV-1-infected women. Methods. Women with positive IGRAs during pregnancy
had four 3-monthly postpartum IGRAs. Postpartum change in magnitude of IFN-γ response was determined using linear mixed
models. Results. Among 18 women with positive pregnancy IGRA, 15 (83%) had a subsequent positive IGRA; 9 (50%) were always
positive, 3 (17%) were always negative, and 6 (33%) ﬂuctuated between positive and negative IGRAs. Women with pregnancy
IGRA IFN-γ>8 spot forming cells (SFCs)/well were more likely to have consistent postpartum IGRA response (odds ratio: 10.0;
95% conﬁdence interval (CI): 0.9–117.0). Change in IFN-γ response over postpartum was 10.2 SFCs/well (95% CI: −1.5–21.8
SFCs/well). Conclusion. Pregnancy positive IGRAs were often maintained postpartum with increased consistency in women with
higher baseline responses. There were modest increases in magnitude of IGRA responses postpartum.
1.Background
Tuberculosis (TB) and human immunodeﬁciency virus type
1 (HIV-1) infection are major health problems in women,
particularly during their reproductive years (15–49) [1]. In
a recent analysis, we observed that HIV-1-infected women
with latent TB infection (LTBI) as detected by a positive
interferon-gamma (IFN-γ) release assay (IGRA) during
pregnancy are at increased risk of active TB during the
postpartum period [2]. Postpartum active TB is associated
with increased risk of mortality in HIV-1-infected women
and their infants and is also associated with an increased




LTBI has traditionally been detected using the tuberculin
skin test (TST), which has limitations in speciﬁcity due to
cross-reactivity with bacille Calmette-Guerin (BCG) vaccine
a n di ns e n s i t i v i t yd u et oa n e r g yi ni m m u n o c o m p r o m i s e d
andmalnourishedindividuals[5].Incontrast,IGRAsarenot
confounded by prior BCG, correlate better with exposure
to active TB than TST, and are not prone to boosting on
repeat testing [5–8]. IGRAs measure immune responses to
MTB antigens: early secretory antigenic target 6-kD protein
(ESAT-6) and culture ﬁltrate protein 10 (CFP-10).2 Infectious Diseases in Obstetrics and Gynecology
While there are data on IGRA performance following
known recent TB exposure or in presence of active TB, little
is known regarding variability of IGRA responses among
individuals without these risk factors [9–12]. In high TB
prevalence settings, 30–50% of individuals have evidence of
latent TB infection (LTBI), and speciﬁc TB exposure may
not be known or deﬁned. Individuals with LTBI would be
expected to have positive IGRA responses; however, these
may vary due to changes in antigenic burden, T-cell response
variability, or test performance. The pregnancy/postpartum
period is associated with hormonal and immunologic
changes during which time it is plausible that MTB-speciﬁc
IGRA responses might ﬂuctuate. Performance of IGRAs
through pregnancy and postpartum has not been described,
overall or in presence of HIV-1 infection.
Using a historical repository from a peripartum HIV-
1 infected cohort, we conducted a study to determine the
magnitude and consistency of IGRA-positive responses over
1 year postpartum in HIV-1-infected women with positive
IGRA responses during pregnancy.
2.MaterialsandMethods
2.1. Ethics Statement. Written informed consent for the
parentstudywasobtainedfromthewomen.HumanSubjects
Division at University of Washington and Ethical Review
Committee at University of Nairobi approved the parent and
current studies.
2.2. Study Design and Population. This study used a speci-
men repository from a historical cohort of HIV-1-infected
women who were enrolled during pregnancy at 32 weeks
gestation and followed for at least 1-year postpartum [13,
14]. As previously reported, we tested 361 women at ∼32-
week gestation with T-SPOT.TB IGRA using cryopreserved
PBMCs; 135 (37.4%) and 170 (47.1%) were positive and
negative, respectively, and 56 (15.5%) had indeterminate
responses [2]. We selected 18 (13.3%) women from the 135
with positive IGRAs who had further specimens available at
postpartum months 3, 6, 9, and 12. Because this study aimed
at deﬁning consistency of IGRAs in absence of active TB, we
excluded women who developed active TB during followup
to avoid changes in IGRAs due to active TB.
2.3. Laboratory Methods. Cryopreserved peripheral blood
mononuclear cells (PBMCs) were tested for IFN-γ responses
using T-SPOT.TB, following the manufacturers’ instructions
on assay procedure and interpretation of results which have
been previously described [2]. The methods used for PBMC
isolation in this cohort have been previously described
[15]. Cells were isolated within 8 hours and were preserved
in freezing medium containing 90% fetal calf serum and
10% dimethyl sulfoxide (DMSO) using a temperature rate
controlled freezing unit overnight at −80◦C and transferred
to liquid nitrogen storage tank within 3 days for long-term
storage. IGRA tests for the previously published study [2]
and the current serial study were conducted by the same
technician in the same laboratory in Nairobi, Kenya.
2.4. Statistical Analysis. The 18 women selected for this serial
assay study were compared with the remaining 117 women
with positive IGRA responses at 32-week gestation using
Student t-tests for means and z-test based on bootstrapped
standard errors to detect diﬀerences in medians for continu-
ous variables, χ2 test (or Fisher’s exact when cell counts were
≤5) for categorical variables.
Women were classiﬁed as consistent responders if they
had positive IGRAs at all four postpartum visits at months 3,
6, 9, and 12, excluding visits with indeterminate responses.
Logistic regression was used to estimate the odds ratio
(OR) of having 100% positive postpartum IGRA responses
and having >50% positive IGRA responses. Women with
combined IFN-γ response (maximum of ESAT-6 or CFP-10-
speciﬁc response abovebackground) during pregnancy of>8
SFCs/well were compared to those with ≤8 SFCs/well. The
cut-point of >8 SFCs/well in the magnitude of pregnancy
IFN-γ response was identiﬁed because this cut-point falls
above the grey zone of 5–7 spots identiﬁed by T-SPOT.TB
manufacturer and by the United States Food and Drug
Administration (FDA) as an indication for retesting and
is the 25th percentile of the magnitude of IFN-γ response
during pregnancy in our data [16, 17].
We used continuous spot count data to estimate the rate
of change in the magnitude of the combined and antigen-
speciﬁc response between postpartum months 3 and 12,
using linear mixed models (LMMs) with random intercepts.
Using the LMMs, we estimated the intraclass correlation
coeﬃcient (ICC), expressed as the within-person variability
in responses as a proportion of the overall variability. Rate of
change in mean postpartum CD4 counts were assessed using
LMM with random intercepts.
Analyses were done using Stata Intercooled v11.1 [18].
3. Results
3.1. Enrollment and Followup. Baseline characteristics (age,
education, and medical history) of the 18 HIV-1-infected
IGRA positive women selected for serial assessment were
comparable to IGRA positive women (n = 117) from the
cohort who were not included in this serial assessment study.
The baseline median CD4 count (518 versus 469 cells/uL,
P = 0.59) and median HIV-1 plasma viral load (4.2 versus
4.7 log10 copies/mL, P = 0.11), baseline median ESAT-6
(16.0 versus 23.5; P = 0.22), and CFP-10 (16.0 versus 23.0;
P = 0.70) were similar between women selected and not
selected for this study, respectively. Among the 18 selected
women, 1 reported having had TB approximately one year
prior to being enrolled in the cohort. At 3, 6, 9, and 12
months, 61%, 44%, 33%, and 33% of women reported
breastfeeding, respectively. None of the women were hospi-
talized or initiated antiretroviral therapy and 5 (28%) were
diagnosed with pneumonia during followup. None of the
women received LTBI treatment during followup because
there was no LTBI testing during the period of cohort
followup and it was not recommended as standard of care.
3.2. Consistency of Postpartum IGRA. Individual positive,
negative, and indeterminate responses at each postpartumInfectious Diseases in Obstetrics and Gynecology 3
Table 1: Interferon-γ release assay results during postpartum in HIV-1-infected women who were interferon-γ release assay positive during
pregnancy.





369 1 2 Consistent‡ positive
postpartum IGRAs
Percent of positive




307 160.5 + + Yes 100.0
237 144 + + + + Yes 100.0
379 119.5 + + + + Yes 100.0
268 79 + + + Yes 100.0
310 42.5 + + + Yes 100.0
330 40 + + + + Yes 100.0
277 24 + + + + Yes 100.0
362 15.5 + + + Yes 100.0
410 8 + + + + Yes 100.0
249 97.5 + − + + No 75.0
300 96.5 + − + + No 75.0
228 8 + + − + No 75.0
381 8 − + + No 66.6
377 64 − + − + No 50.0
287 6 −−+ No 33.0
376 120 −−− No 0.0
265 7.5 −−−− No 0.0
233 7 −−− No 0.0
Note: IGRA interferon-gamma release assay.
This table is sorted by consistency of positive postpartum IGRAs. The ﬁrst nine rows display IGRA responses in women who had all positive postpartum
IGRAs. The next 6 rows display IGRA responses in women who ﬂuctuated between positive and negative IGRAs postpartum. The last 3 rows display IGRA
responses in women who had all negative postpartum IGRA.
∗Maximum of ESAT-6/CPF-10 minus negative control.
†Blank cells represent visits with indeterminate responses.
‡Consistent positive IGRAs is deﬁned as all postpartum visits with positive IGRAs, excluding visits with indeterminate responses.
visit are shown in Table 1. Of the 72 (18 women × 4 post-
partum time points) tests performed, 9 (12.5%) were inde-
terminate. Excluding visits with indeterminate responses,
83.3% of women had a postpartum positive IGRA, 50%
(9/18) had positive IGRA response at all postpartum visits,
33.3% (6/18) had responses ﬂuctuating between positive
and negative, and 16.7% (3/18) had negative IGRAs at all
postpartum visits.
3.3. Pregnancy IFN-γ Response and Consistency of Postpar-
tum IGRAs. Women with combined IFN-γ response >8
SFCs/well during pregnancy were 10 times more likely
to have consistently positive IGRAs postpartum compared
to women with ≤8 SFCs/well (OR: 10.0; 95% conﬁdence
interval (CI): 0.85–117.0; P = 0.07) (Table 2(a)) and 5 times
more likely to have >50% of postpartum visits with positive
IGRAs (OR: 5.0; 95% CI: 0.55–45.39; P = 0.15) (Table 2(b)).
Median magnitude of a combined IFN-γ response during
postpartum in women with baseline IFN-γ response of >8
versus ≤8 SFCs/well is displayed in Figure 1.
3.4. Change in Magnitude of Postpartum IFN-γ Response.
Median magnitude of the combined IFN-γ and antigen-
speciﬁc responses over postpartum are shown in Figure 2.
Using a LMM with random intercepts, the average rate of
change in magnitude (SFCs/well) per 3 monthly visits was
estimated to be 10.2 (95% CI: −1.5–21.8; P = 0.09) for
the combined postpartum IFN-γ response and 5.0 (95% CI:
−3.2–13.1; P = 0.23) and 7.2 (95% CI: −3.0–17.2; P =
0.17) for ESAT-6 and CFP-10 responses, respectively. Using
this model, we estimated an ICC of 0.51, 0.61, and 0.41
for combined, ESAT-6 and CFP-10 responses, respectively,
suggesting substantial within-person variability in IGRA
responses.
The average rate of decline in CD4 count between
months 3 and 12 was −24.0 cells/mm3 per 3 monthly
visit (95% CI: −57.6–9.6; P = 0.16) using a LMM with
random intercepts. Change in CD4 count was plotted
against the change in magnitude of the combined IFN-
γ response and ESAT-6 and CFP-10 responses. Adjusted
analyses incorporating CD4 did not alter estimates for rate
of change in IFN-γ response.4 Infectious Diseases in Obstetrics and Gynecology
Table 2: (a) Odds of consistently positive interferon-γ release assays in women associated with baseline magnitude of interferon-γ response
>8 compared to ≤8 SFCs/well. (b) Odds of >50% postpartum visits with positive interferon-γ release assays in women with baseline
magnitude of interferon-γ response >8 compared to ≤8S F C s / w e l l .
(a)
Postpartum consistency of IGRAs
Interferon-γ response∗
(SFCs/well) during pregnancy Yes No Odds ratio (95% conﬁdence interval); P
value
>88 4 10.0 (0.85–117.0); 0.07
≤81 5
(b)
Greater than 50% postpartum visits with positive IGRAs
Interferon-γ response∗
(SFCs/well) during pregnancy Yes No Odds ratio (95% conﬁdence interval); P
value
>81 0 2 5.0 (0.55–45.39); 0.15
≤83 3
Note: IGRA interferon-gamma release assay.
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Figure 1: Change in magnitude of postpartum interferon-γ
response by baseline interferon-γ response. The dash and dotted
line represents women with baseline interferon-γ response of >8
SFCs/well, and the solid line represents women with baseline
interferon-γ response of ≤8 SFCs/well. The horizontal dashed line
corresponds to the manufacturer deﬁned cut-point at 6 SFCs/well
above background for a positive response and the dotted horizontal
line represents 8 SFCs/well. Interferon-γ response is deﬁned as the
maximum of ESAT-6/CFP-10 minus spot count in negative control.
4. Discussion
In this study, we serially tested 18 HIV-1-infected women
who were IGRA-positive at baseline during pregnancy, at
3 monthly intervals during the ﬁrst-year postpartum to
determine long-term within-person consistency of IGRA
responses and to describe the eﬀect of the peripartum
period on IGRA responses. We observed that 83% of women
had a subsequent positive response and 50% retained a
positive IGRA response at all subsequent assays throughout
the postpartum period. Women with higher magnitude of
combined response at baseline were more likely to have
consistently positive responses at subsequent time points.
Women with weak positive response close to the cut-
oﬀ value at baseline had subsequently ﬂuctuating IGRA
responses. The magnitude of the combined IFN-γ response
and antigen-speciﬁc responses increased slightly during the
1-year postpartum period.
Our study was conducted in a setting with high TB
incidence in HIV-1-infected women with high probability
of TB exposure but no speciﬁc known TB exposure. We
found that HIV-1-infected pregnant women with latent
TB infection had generally reproducible positive IGRA
responses. Although 2011 WHO guidelines recommend
universal isoniazid preventive therapy (IPT) in HIV-1-
infected individuals, IGRA-targeted IPT may be a strategy to
consider for pregnant women [19]. Consistent detection of
latent TB by IGRAs despite physiologic changes during/after
pregnancy would strengthen speciﬁcity of this approach.
While most women had repeated positive IGRAs in our
study, we observed some reversions and noted within-person
variability of responses, which could be due to changes in
TB exposure, TB immune responses, or test reproducibility.
Our observation of ﬂuctuation in responses is consistent
with previous serial IGRA studies, in which conversions and
reversionswereobservedmorefrequentlyinindividualswith
responses close to the predeﬁned cut-point for a positive
response [20–22]. One South African study with close repeat
testing (2 days apart) of 15 health care workers (HCWs)
noted 100% concordance in results [23]. However, in TB-
exposed HCWs in India with serial IGRAs, 2/14 (14%) had a
change in QFT responses with magnitude of IFN-γ declining
12 days after baseline assessment [21]. Another study in
HCWs in South Africa using both QFT and T-SPOT.TB
at 4 times over 21 days observed that T-SPOT responses
were more likely to change (revert/convert) than QFT and
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Figure 2: Change in magnitude of interferon-γ and antigen-speciﬁc response during postpartum. The solid lines represent the median
response, and the two dashed lines represent the 25th and 75th percentiles of the response. The horizontal dotted line represents the
manufacturer deﬁned cut-point at 6 SFCs/well above background for a positive response. Interferon-γ response∗ is deﬁned as the maximum
of ESAT-6/CFP-10 minus spot count in negative control.
[20]. Finally, among HCWs in Germany, a low TB incidence
country, there were more reversions than conversions during
serial testing and age and prior positive TST predicted
consistent QFT positivity [22].
In our study, women with baseline response of >8
SFCs/well were 10 times more likely to have consistently
positive IGRAs postpartum while those with lower levels
had less consistent responses. These data are consistent with
previous studies noting that responses close to the cut-
point are more likely to ﬂuctuate [20–22] .T h eU SF D Aa n d
Oxford Immunotec recommend a borderline “grey zone”
of 5–7 spots above negative control for the T-SPOT.TB
and suggest that results be considered in conjunction with
clinical information or to retest [16, 17]. We also observed
a substantial within person variability in the quantita-
tive responses, which probably accounts for much of the
ﬂuctuation in the qualitative responses between positive
and negative. These ﬁndings underscore the importance of
considering quantitative IFN-γ response data in addition to
the dichotomous (positive/negative) results in serial testing
and in clinical decisions.
Our study has important strengths and limitations. Our
study is the ﬁrst to describe long-term within-person repro-
ducibility of T-SPOT.TB IGRA in HIV-1-infected women
during the pregnancy/postpartum period in a TB-endemic
setting in the absence of any speciﬁc exposure to TB. The
women included in this study had longitudinally measured
clinical and immunological outcomes, enabling us to take
these factors into account since they could potentially
alter IGRA responses. We were also able to repeat the
IGRAs for these women at relatively close intervals and at
critical time points such as early postpartum and during
breastfeeding. Our study involves women without a deﬁned
time of TB exposure or LTBI treatment. This enabled us
to describe the natural variation in IFN-γ responses during
the pregnancy/postpartum period. In contrast to previous
studies on serial IGRAs, which have been typically shorter,
our period of serial evaluation was longer (over 1 year).
A limitation of our study was the use of cryopreserved
PBMCs as opposed to fresh samples, which might have
contributed to test variability [24]. In a previous study
of T-SPOT.TB results comparing fresh and frozen PBMCs,
cryopreserved samples had lower sensitivity [25]. In our
study, lower sensitivity due to cryopreserved PBMCs may
have contributed to greater ﬂuctuation of results between
positive and negative. However, a new serial assessment
study using fresh assays would not be feasible because a
positive test would indicate LTBI treatment based on new
guidelines. In addition, a few published studies have noted
adequacy of cryopreserved samples for T.SPOT.TB and other
ELISpot assays [26, 27]. A design constraint of studying LTBI
responsesinthissettingisthatwomenarefrequentlyexposed
to TB. Thus, the alternative design including women who
were IGRA negative at baseline and followed for consistency
of “negative” responses would be confounded by women
with new positive IGRAs who newly acquired LTBI. We
therefore restricted the study to those with baseline positive
IGRAs to assess consistency. Selective inclusion of baseline
positives would be expected to bias estimates of rate of
change in IFN-γ response. To circumvent this potential bias,
weevaluatedchangesafterthebaselinevisit.Oursamplesize,
though small, was comparable or larger than previous serial
studies on IGRAs.
In conclusion, our study demonstrates consistency of
IGRAs during pregnancy and postpartum in HIV-1-infected
women, particularly among those with higher magnitude6 Infectious Diseases in Obstetrics and Gynecology
responses. Fluctuation in responses between positive and
negative was seen among women with weak positive
responses at baseline. Despite hormonal and immune per-
turbations during the postpartum period, the magnitude
of response did not change markedly over the postpartum
period, as shown by the results from the linear mixed
models. The slight increase in levels over time during the
postpartum period may reﬂect some impact of immuno-
suppression during pregnancy, which may explain increased
susceptibility to active TB during this period. The burden
of TB in HIV-1-infected women in the childbearing years
and the consequent risk of TB morbidity and mortality
in their infants is well established [1–4, 28–31]. Further
serial studies in this setting will be useful to deﬁne optimal
timing for IGRA testing during or after pregnancy and to
understand biologic determinants of IGRA responses and
magnitude.
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